Curaleaf Holdings (CURLF) Share-based Compensation (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Share-based Compensation of -$20.4 million for Q4 2024, down 449.26% year-over-year from $5.8 million in Q1 2024, and down 438.52% quarter-over-quarter from $6.0 million in Q3 2024.
Curaleaf Holdings (CURLF) Share-based Compensation (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Share-based Compensation history runs 6 years deep, the most recent figure standing at -$20.4 million for Q4 2024.
- In Q4 2024, Share-based Compensation fell 449.26% year-over-year to -$20.4 million; the TTM figure through Dec 2024 stood at -$2.3 million (down 138.81% YoY), while the FY2025 annual figure was $35.7 million, changed N/A from the prior year.
- Share-based Compensation for Q4 2024 stood at -$20.4 million, down from $6.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $18.4 million in Q2 2021, with the low at -$20.4 million in Q4 2024.
- The 5-year median for Share-based Compensation is $5.9 million (2023), against an average of $4.5 million.
- The sharpest annual moves came in 2021 and 2022: Share-based Compensation soared 189.25% in 2021, then slumped 633.27% in 2022.
- Curaleaf Holdings' Share-based Compensation stood at $13.1 million in 2020, then sank by 76.88% to $3.0 million in 2021, then plunged by 633.27% to -$16.1 million in 2022, then jumped by 136.17% to $5.8 million in 2023, then slumped by 449.26% to -$20.4 million in 2024.
- Business Quant data shows CURLF's Share-based Compensation at -$20.4 million in Q4 2024, $6.0 million in Q3 2024, and $5.8 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -20.37 Mn |
| Dec 31, 2024 | -20.37 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Dec 31, 2023 | 5.83 Mn |
| Dec 31, 2023 | 5.83 Mn |
| Sep 30, 2023 | 6.22 Mn |
| Sep 30, 2023 | 6.22 Mn |
| Dec 31, 2022 | -16.13 Mn |
| Dec 31, 2022 | -16.13 Mn |
| Sep 30, 2022 | 9.99 Mn |
| Sep 30, 2022 | 9.99 Mn |
| Jun 30, 2022 | 6.04 Mn |
| Jun 30, 2022 | 6.04 Mn |
| Mar 31, 2022 | 5.09 Mn |
| Mar 31, 2022 | 5.09 Mn |
| Dec 31, 2021 | 3.02 Mn |
| Dec 31, 2021 | 3.02 Mn |
| Sep 30, 2021 | 13.18 Mn |
| Sep 30, 2021 | 13.18 Mn |